Related references
Note: Only part of the references are listed.Lactobacillus gasseri in the Upper Small Intestine Impacts an ACSL3-Dependent Fatty Acid-Sensing Pathway Regulating Whole-Body Glucose Homeostasis
Paige V. Bauer et al.
CELL METABOLISM (2018)
Metformin Alters Upper Small Intestinal Microbiota that Impact a Glucose-SGLT1-Sensing Glucoregulatory Pathway
Paige V. Bauer et al.
CELL METABOLISM (2018)
Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism
Preeti Pathak et al.
HEPATOLOGY (2018)
Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman et al.
NATURE MEDICINE (2018)
Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo
Anila K. Madiraju et al.
NATURE MEDICINE (2018)
Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography
Melanie Deschasaux et al.
NATURE MEDICINE (2018)
An Intestinal Farnesoid X Receptor-Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice
Cen Xie et al.
DIABETES (2017)
Microbiota-induced obesity requires farnesoid X receptor
Ava Parseus et al.
GUT (2017)
GUT MICROBIOTA Mucin-munching bacteria modulate glucose metabolism
Tim Geach
NATURE REVIEWS ENDOCRINOLOGY (2017)
Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism
Preeti Pathak et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Ursodeoxycholic Acid Suppresses Lipogenesis in Mouse Liver: Possible Role of the Decrease in β-Muricholic Acid, a Farnesoid X Receptor Antagonist
Kyosuke Fujita et al.
LIPIDS (2017)
Metformin-resistant folic acid producing probiotics or folic acid against metformin's adverse effects like diarrhea
Abdullah Olgun
MEDICAL HYPOTHESES (2017)
Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug
Hao Wu et al.
NATURE MEDICINE (2017)
The mechanisms of action of metformin
Graham Rena et al.
DIABETOLOGIA (2017)
Pseudoalignment for metagenomic read assignment
L. Schaeffer et al.
BIOINFORMATICS (2017)
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism
Annika Wahlstrom et al.
CELL METABOLISM (2016)
Altered Microbiota Contributes to Reduced Diet-Induced Obesity upon Cold Exposure
Marika Zietak et al.
CELL METABOLISM (2016)
An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease
Frank J. Gonzalez et al.
GASTROENTEROLOGY (2016)
Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans
Shogo Takahashi et al.
JOURNAL OF LIPID RESEARCH (2016)
Signals from the gut microbiota to distant organs in physiology and disease
Bjoern Schroeder et al.
NATURE MEDICINE (2016)
Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism
Limin Zhang et al.
MSYSTEMS (2016)
Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity
Michaela Mueller et al.
JOURNAL OF HEPATOLOGY (2015)
Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
Kristoffer Forslund et al.
NATURE (2015)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vetizou et al.
SCIENCE (2015)
Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells
Mohamed-Sami Trabelsi et al.
NATURE COMMUNICATIONS (2015)
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Changtao Jiang et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Effect of Metformin on Metabolic Improvement and Gut Microbiota
Heetae Lee et al.
APPLIED AND ENVIRONMENTAL MICROBIOLOGY (2014)
An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice
Na-Ri Shin et al.
GUT (2014)
Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk
Fleur Lien et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Anila K. Madiraju et al.
NATURE (2014)
Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus
Antonella Napolitano et al.
PLOS ONE (2014)
Metformin as adjunct antituberculosis therapy
Amit Singhal et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Microbiota Modification with Probiotics Induces Hepatic Bile Acid Synthesis via Downregulation of the Fxr-Fgf15 Axis in Mice
Chiara Degirolamo et al.
CELL REPORTS (2014)
Metformin Retards Aging in C. elegans by Altering Microbial Folate and Methionine Metabolism
Filipe Cabreiro et al.
CELL (2013)
Pleiotropic Roles of Bile Acids in Metabolism
Thomas Q. de Aguiar Vallim et al.
CELL METABOLISM (2013)
Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist
Sama I. Sayin et al.
CELL METABOLISM (2013)
FXR signaling in the enterohepatic system
Tsutomu Matsubara et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice
Bo Kong et al.
HEPATOLOGY (2012)
Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice
Takuma Tsuchida et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2012)
Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cells
Daisuke Nakada et al.
NATURE (2010)
Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064
Adwoa Akwabi-Ameyaw et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Metformin and the intestine
C. J. Bailey et al.
DIABETOLOGIA (2008)
Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine
Insook Kim et al.
JOURNAL OF LIPID RESEARCH (2007)
Role of AMP-activated protein kinase in mechanism of metformin action
GC Zhou et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Share Paper
